2026 Q1 -tulosraportti
Vain PDF
71 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenI have come across this study that Weed.de has conducted and which was published yesterday. As you can see, the people who receive a prescription for Weeco Astrum10-10 (the others too) have gone through a long treatment process, several years in fact, before they receive a prescription for Weeco Astrum10-10, which is in line with the arguments I have put forward previously, that the new legislative proposal has NO impact whatsoever on Stenocare's earnings in Germany. When it says that people lose their prescription, it is only flowers and vaporizers that lose their subsidy. It is Weed.de that is responsible for the study and they lose a lot of money because the subsidy is removed from flowers and vaporizers, but as I said, Stenocare only earns money from oil in Germany, and therefore everything continues as usual for Stenocare. https://cannabib.de/schlagzeilen/cannabis-auf-kassenrezept-2026-gkv-reform/I would like to add that there have been several whispers circulating that I only show positive news about Weeco Astrum10-10 in Germany, If you can find negative news from Germany, please share them here on Nordnet social. I myself look for negative news in Germany every day, but there isn't any at the moment. I couldn't help but think that this is too good to be true. Stenocare has been trying to gain a foothold in Germany since 2022, and almost out of the blue, there are 8 large platforms that have adopted the oil, and doctors have started prescribing Weeco Astrum 10-10????? Because there is so much commotion about the subsidy being removed, a lot is being written about it, and when I put the pieces together, it gives a clear picture of what is happening in Germany right now. It is luck upon luck, and skill from ADREX Pharma, that Stenocare received these coveted advantages. Approval, 100% reimbursement and fast track in 2025, in hindsight, now that flowers and vapes are losing their subsidy. This subsidy has been discussed in Germany, and Nina Warken, who is now Minister of Health, has been an ardent opponent of flowers and vapes also receiving subsidies. Now that she is Minister of Health, she gets her way in removing the mentioned subsidy, because she can document that the subsidy has blown the budget. Weeco Pharma could see the writing on the wall, and that is why they have started to include oil in their assortment. Stenocare was lacking a distributor, a perfect match. Because Weeco Pharma also needs to have a decent income after January 1, 2027, they have been very aggressive with their campaign for the oil, and that is also the reason why the 8 online platforms have adopted the oil, because they will also lose money if they just let things slide. Although it was naturally not the intention, the new law benefits Stenocare's revenues, and it is because of the new law that Weeco Pharma has adopted Stenocare's oil. When TS and PJ have claimed that Germany will be very valuable for Stenocare's earnings, we can trust that. Now we just need to see proof of it when Weeco Pharma has settled with Stenocare. Or the very short version, follow the money.- ·2 päivää sitten · MuokattuFollowing yesterday's news, regarding the approval of the bill, in the Bundestag. As I wrote yesterday, this approval will not affect Weeco Astrum10-10, and here is the explanation. I read several articles, and in none of them was the Weeco Astrum10-10 consequence mentioned. I wondered about that, so I made one of the journalists aware that Weeco Astrum10-10 is also approved in Germany. To make a long story short, it ended with me having to prove that Weeco Astrum10-10 is approved in Germany. A few hours later, I found out that even in this area, it is not normal, in Germany. Because I found out that there are several different approvals in Germany, tsk tsk tsk. Nothing is so bad that it isn't good for something else, because it has turned out to be an advantage for Weeco Astrum10-10 not to be approved for anything specific. The explanation follows below. When exactly these four different preparations are mentioned in all the articles, it is because these preparations are approved for specific diseases. e.g. Sativex is specifically approved for one particular disease, multiple sclerosis (MS), and doctors may in principle only prescribe Sativex for this disease, and the others are specifically approved for something else and may only be prescribed for that. These four preparations have all gone the hard way, with phase 1, 2 and 3. Therefore, doctors may prescribe these preparations as a first choice. Weeco Astrum10-10 is not approved for any specific diseases. This is why doctors may not start by prescribing Weeco Astrum10-10, but only when it has been shown that the other products do not work. And because Weeco Astrum10-10 is not approved for any specific disease, doctors may write prescriptions for Weeco Astrum10-10 for all diseases that are approved for cannabis medicine. Therefore, this bill, which was discussed yesterday, has no impact on the sale of Weeco Astrum10-10. The people who have received prescriptions for Weeco Astrum10-10 will continue to do so. But those who pay themselves may get a prescription immediately, and therefore do not have to wait 6 months. If you have managed to read this post before I have corrected it, then these 4 preparations have retained their status, that doctors may prescribe prescriptions as a first choice.
We probably won't agree, and that's fine. I just still think you're dismissing a potential risk a bit too quickly. I still believe that if the law ends up being implemented in the draft that has been presented, then I do not see it as an advantage – neither for new patients nor for the possibility of continued growth in Germany. Let's see what happens over the summer. I certainly hope the law is not passed in its current form, as I believe it will be a clear deterioration for the patients. - ·3 päivää sittenstock status When it became known that flowers and vapes would lose their subsidy, as of January 1, 2027, I wrote that I would keep an eye on some online stores that only have flowers and vapes in their assortment, to find out if they start to stock oils and extracts. The reason this is interesting for us is that if they start to have oils in their assortment, it's only because they expect flowers to go down and oils to go up in earnings. Canation.com: has prepared to stock oils. Canation has until now only stocked flowers, but now they are preparing to also stock oils and extracts. As I wrote earlier, Weeco Pharma has a big campaign this summer, after it became known that the subsidy stops. The campaign is targeted at companies that only stock flowers, because Weeco Pharma wants Weeco Astrum10-10 to also become part of their assortment. As I wrote, the others also have such a campaign running. Flowers and vapes have been a huge business in Germany, and therefore Canation has only had flowers in their assortment, so when they prepare to also have oils and extracts in their assortment, it means that they expect the flower business to go down and oil to go up. That was the first of the online stores that I follow. Just for the record, we don't know which brand(s) they have chosen to stock yet.
- ·10.7.I only discovered this today. Weeco Pharma has been at the EU's largest cannabis fair for professionals such as pharmacists and dealers. Weeco Astrum10-10 was part of their campaign already at the fair, which may be the reason why it has been possible for Weeco Pharma that so many doctors, in such a short time, have become aware of the oil. https://weeco.com/en/2026/02/13/weeco-will-be-present-at-the-icbc-in-berlin-on-april-13th-and-15th/It's also nothing new that there is risk in investing in stocks, and that applies to all stocks, there are no safe stocks, see what has happened with Novo Nordisk, just to give an example of a stock that was considered a safe investment. The only thing I am impatient about is to find out how much Stenocare has earned in Q2, in Germany. Tomorrow it will be 14 days since Q2 closed, and since both pharmacies and the various distributors have been digitized in Germany, Weeco Pharma must soon have finished calculating what Stenocare has earned in Germany. Regardless of the amount's size, it is much more than TS and PJ have announced, since they have stated that there will be 0 kr. in earnings from Germany in 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
71 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenI have come across this study that Weed.de has conducted and which was published yesterday. As you can see, the people who receive a prescription for Weeco Astrum10-10 (the others too) have gone through a long treatment process, several years in fact, before they receive a prescription for Weeco Astrum10-10, which is in line with the arguments I have put forward previously, that the new legislative proposal has NO impact whatsoever on Stenocare's earnings in Germany. When it says that people lose their prescription, it is only flowers and vaporizers that lose their subsidy. It is Weed.de that is responsible for the study and they lose a lot of money because the subsidy is removed from flowers and vaporizers, but as I said, Stenocare only earns money from oil in Germany, and therefore everything continues as usual for Stenocare. https://cannabib.de/schlagzeilen/cannabis-auf-kassenrezept-2026-gkv-reform/I would like to add that there have been several whispers circulating that I only show positive news about Weeco Astrum10-10 in Germany, If you can find negative news from Germany, please share them here on Nordnet social. I myself look for negative news in Germany every day, but there isn't any at the moment. I couldn't help but think that this is too good to be true. Stenocare has been trying to gain a foothold in Germany since 2022, and almost out of the blue, there are 8 large platforms that have adopted the oil, and doctors have started prescribing Weeco Astrum 10-10????? Because there is so much commotion about the subsidy being removed, a lot is being written about it, and when I put the pieces together, it gives a clear picture of what is happening in Germany right now. It is luck upon luck, and skill from ADREX Pharma, that Stenocare received these coveted advantages. Approval, 100% reimbursement and fast track in 2025, in hindsight, now that flowers and vapes are losing their subsidy. This subsidy has been discussed in Germany, and Nina Warken, who is now Minister of Health, has been an ardent opponent of flowers and vapes also receiving subsidies. Now that she is Minister of Health, she gets her way in removing the mentioned subsidy, because she can document that the subsidy has blown the budget. Weeco Pharma could see the writing on the wall, and that is why they have started to include oil in their assortment. Stenocare was lacking a distributor, a perfect match. Because Weeco Pharma also needs to have a decent income after January 1, 2027, they have been very aggressive with their campaign for the oil, and that is also the reason why the 8 online platforms have adopted the oil, because they will also lose money if they just let things slide. Although it was naturally not the intention, the new law benefits Stenocare's revenues, and it is because of the new law that Weeco Pharma has adopted Stenocare's oil. When TS and PJ have claimed that Germany will be very valuable for Stenocare's earnings, we can trust that. Now we just need to see proof of it when Weeco Pharma has settled with Stenocare. Or the very short version, follow the money.
- ·2 päivää sitten · MuokattuFollowing yesterday's news, regarding the approval of the bill, in the Bundestag. As I wrote yesterday, this approval will not affect Weeco Astrum10-10, and here is the explanation. I read several articles, and in none of them was the Weeco Astrum10-10 consequence mentioned. I wondered about that, so I made one of the journalists aware that Weeco Astrum10-10 is also approved in Germany. To make a long story short, it ended with me having to prove that Weeco Astrum10-10 is approved in Germany. A few hours later, I found out that even in this area, it is not normal, in Germany. Because I found out that there are several different approvals in Germany, tsk tsk tsk. Nothing is so bad that it isn't good for something else, because it has turned out to be an advantage for Weeco Astrum10-10 not to be approved for anything specific. The explanation follows below. When exactly these four different preparations are mentioned in all the articles, it is because these preparations are approved for specific diseases. e.g. Sativex is specifically approved for one particular disease, multiple sclerosis (MS), and doctors may in principle only prescribe Sativex for this disease, and the others are specifically approved for something else and may only be prescribed for that. These four preparations have all gone the hard way, with phase 1, 2 and 3. Therefore, doctors may prescribe these preparations as a first choice. Weeco Astrum10-10 is not approved for any specific diseases. This is why doctors may not start by prescribing Weeco Astrum10-10, but only when it has been shown that the other products do not work. And because Weeco Astrum10-10 is not approved for any specific disease, doctors may write prescriptions for Weeco Astrum10-10 for all diseases that are approved for cannabis medicine. Therefore, this bill, which was discussed yesterday, has no impact on the sale of Weeco Astrum10-10. The people who have received prescriptions for Weeco Astrum10-10 will continue to do so. But those who pay themselves may get a prescription immediately, and therefore do not have to wait 6 months. If you have managed to read this post before I have corrected it, then these 4 preparations have retained their status, that doctors may prescribe prescriptions as a first choice.We probably won't agree, and that's fine. I just still think you're dismissing a potential risk a bit too quickly. I still believe that if the law ends up being implemented in the draft that has been presented, then I do not see it as an advantage – neither for new patients nor for the possibility of continued growth in Germany. Let's see what happens over the summer. I certainly hope the law is not passed in its current form, as I believe it will be a clear deterioration for the patients.
- ·3 päivää sittenstock status When it became known that flowers and vapes would lose their subsidy, as of January 1, 2027, I wrote that I would keep an eye on some online stores that only have flowers and vapes in their assortment, to find out if they start to stock oils and extracts. The reason this is interesting for us is that if they start to have oils in their assortment, it's only because they expect flowers to go down and oils to go up in earnings. Canation.com: has prepared to stock oils. Canation has until now only stocked flowers, but now they are preparing to also stock oils and extracts. As I wrote earlier, Weeco Pharma has a big campaign this summer, after it became known that the subsidy stops. The campaign is targeted at companies that only stock flowers, because Weeco Pharma wants Weeco Astrum10-10 to also become part of their assortment. As I wrote, the others also have such a campaign running. Flowers and vapes have been a huge business in Germany, and therefore Canation has only had flowers in their assortment, so when they prepare to also have oils and extracts in their assortment, it means that they expect the flower business to go down and oil to go up. That was the first of the online stores that I follow. Just for the record, we don't know which brand(s) they have chosen to stock yet.
- ·10.7.I only discovered this today. Weeco Pharma has been at the EU's largest cannabis fair for professionals such as pharmacists and dealers. Weeco Astrum10-10 was part of their campaign already at the fair, which may be the reason why it has been possible for Weeco Pharma that so many doctors, in such a short time, have become aware of the oil. https://weeco.com/en/2026/02/13/weeco-will-be-present-at-the-icbc-in-berlin-on-april-13th-and-15th/It's also nothing new that there is risk in investing in stocks, and that applies to all stocks, there are no safe stocks, see what has happened with Novo Nordisk, just to give an example of a stock that was considered a safe investment. The only thing I am impatient about is to find out how much Stenocare has earned in Q2, in Germany. Tomorrow it will be 14 days since Q2 closed, and since both pharmacies and the various distributors have been digitized in Germany, Weeco Pharma must soon have finished calculating what Stenocare has earned in Germany. Regardless of the amount's size, it is much more than TS and PJ have announced, since they have stated that there will be 0 kr. in earnings from Germany in 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
71 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenI have come across this study that Weed.de has conducted and which was published yesterday. As you can see, the people who receive a prescription for Weeco Astrum10-10 (the others too) have gone through a long treatment process, several years in fact, before they receive a prescription for Weeco Astrum10-10, which is in line with the arguments I have put forward previously, that the new legislative proposal has NO impact whatsoever on Stenocare's earnings in Germany. When it says that people lose their prescription, it is only flowers and vaporizers that lose their subsidy. It is Weed.de that is responsible for the study and they lose a lot of money because the subsidy is removed from flowers and vaporizers, but as I said, Stenocare only earns money from oil in Germany, and therefore everything continues as usual for Stenocare. https://cannabib.de/schlagzeilen/cannabis-auf-kassenrezept-2026-gkv-reform/I would like to add that there have been several whispers circulating that I only show positive news about Weeco Astrum10-10 in Germany, If you can find negative news from Germany, please share them here on Nordnet social. I myself look for negative news in Germany every day, but there isn't any at the moment. I couldn't help but think that this is too good to be true. Stenocare has been trying to gain a foothold in Germany since 2022, and almost out of the blue, there are 8 large platforms that have adopted the oil, and doctors have started prescribing Weeco Astrum 10-10????? Because there is so much commotion about the subsidy being removed, a lot is being written about it, and when I put the pieces together, it gives a clear picture of what is happening in Germany right now. It is luck upon luck, and skill from ADREX Pharma, that Stenocare received these coveted advantages. Approval, 100% reimbursement and fast track in 2025, in hindsight, now that flowers and vapes are losing their subsidy. This subsidy has been discussed in Germany, and Nina Warken, who is now Minister of Health, has been an ardent opponent of flowers and vapes also receiving subsidies. Now that she is Minister of Health, she gets her way in removing the mentioned subsidy, because she can document that the subsidy has blown the budget. Weeco Pharma could see the writing on the wall, and that is why they have started to include oil in their assortment. Stenocare was lacking a distributor, a perfect match. Because Weeco Pharma also needs to have a decent income after January 1, 2027, they have been very aggressive with their campaign for the oil, and that is also the reason why the 8 online platforms have adopted the oil, because they will also lose money if they just let things slide. Although it was naturally not the intention, the new law benefits Stenocare's revenues, and it is because of the new law that Weeco Pharma has adopted Stenocare's oil. When TS and PJ have claimed that Germany will be very valuable for Stenocare's earnings, we can trust that. Now we just need to see proof of it when Weeco Pharma has settled with Stenocare. Or the very short version, follow the money.
- ·2 päivää sitten · MuokattuFollowing yesterday's news, regarding the approval of the bill, in the Bundestag. As I wrote yesterday, this approval will not affect Weeco Astrum10-10, and here is the explanation. I read several articles, and in none of them was the Weeco Astrum10-10 consequence mentioned. I wondered about that, so I made one of the journalists aware that Weeco Astrum10-10 is also approved in Germany. To make a long story short, it ended with me having to prove that Weeco Astrum10-10 is approved in Germany. A few hours later, I found out that even in this area, it is not normal, in Germany. Because I found out that there are several different approvals in Germany, tsk tsk tsk. Nothing is so bad that it isn't good for something else, because it has turned out to be an advantage for Weeco Astrum10-10 not to be approved for anything specific. The explanation follows below. When exactly these four different preparations are mentioned in all the articles, it is because these preparations are approved for specific diseases. e.g. Sativex is specifically approved for one particular disease, multiple sclerosis (MS), and doctors may in principle only prescribe Sativex for this disease, and the others are specifically approved for something else and may only be prescribed for that. These four preparations have all gone the hard way, with phase 1, 2 and 3. Therefore, doctors may prescribe these preparations as a first choice. Weeco Astrum10-10 is not approved for any specific diseases. This is why doctors may not start by prescribing Weeco Astrum10-10, but only when it has been shown that the other products do not work. And because Weeco Astrum10-10 is not approved for any specific disease, doctors may write prescriptions for Weeco Astrum10-10 for all diseases that are approved for cannabis medicine. Therefore, this bill, which was discussed yesterday, has no impact on the sale of Weeco Astrum10-10. The people who have received prescriptions for Weeco Astrum10-10 will continue to do so. But those who pay themselves may get a prescription immediately, and therefore do not have to wait 6 months. If you have managed to read this post before I have corrected it, then these 4 preparations have retained their status, that doctors may prescribe prescriptions as a first choice.We probably won't agree, and that's fine. I just still think you're dismissing a potential risk a bit too quickly. I still believe that if the law ends up being implemented in the draft that has been presented, then I do not see it as an advantage – neither for new patients nor for the possibility of continued growth in Germany. Let's see what happens over the summer. I certainly hope the law is not passed in its current form, as I believe it will be a clear deterioration for the patients.
- ·3 päivää sittenstock status When it became known that flowers and vapes would lose their subsidy, as of January 1, 2027, I wrote that I would keep an eye on some online stores that only have flowers and vapes in their assortment, to find out if they start to stock oils and extracts. The reason this is interesting for us is that if they start to have oils in their assortment, it's only because they expect flowers to go down and oils to go up in earnings. Canation.com: has prepared to stock oils. Canation has until now only stocked flowers, but now they are preparing to also stock oils and extracts. As I wrote earlier, Weeco Pharma has a big campaign this summer, after it became known that the subsidy stops. The campaign is targeted at companies that only stock flowers, because Weeco Pharma wants Weeco Astrum10-10 to also become part of their assortment. As I wrote, the others also have such a campaign running. Flowers and vapes have been a huge business in Germany, and therefore Canation has only had flowers in their assortment, so when they prepare to also have oils and extracts in their assortment, it means that they expect the flower business to go down and oil to go up. That was the first of the online stores that I follow. Just for the record, we don't know which brand(s) they have chosen to stock yet.
- ·10.7.I only discovered this today. Weeco Pharma has been at the EU's largest cannabis fair for professionals such as pharmacists and dealers. Weeco Astrum10-10 was part of their campaign already at the fair, which may be the reason why it has been possible for Weeco Pharma that so many doctors, in such a short time, have become aware of the oil. https://weeco.com/en/2026/02/13/weeco-will-be-present-at-the-icbc-in-berlin-on-april-13th-and-15th/It's also nothing new that there is risk in investing in stocks, and that applies to all stocks, there are no safe stocks, see what has happened with Novo Nordisk, just to give an example of a stock that was considered a safe investment. The only thing I am impatient about is to find out how much Stenocare has earned in Q2, in Germany. Tomorrow it will be 14 days since Q2 closed, and since both pharmacies and the various distributors have been digitized in Germany, Weeco Pharma must soon have finished calculating what Stenocare has earned in Germany. Regardless of the amount's size, it is much more than TS and PJ have announced, since they have stated that there will be 0 kr. in earnings from Germany in 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt